To Whom It May Concern:

has alopecia areata, a common autoimmune disease that causes loss of hair on the scalp and elsewhere on the body. It usually starts with one or more small, round, smooth patches on the scalp and can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis).

Alopecia areata is associated with serious comorbidities that are debilitating for patients and contribute to a significant healthcare burden [1,2,3]. Patients experience higher rates of depression, anxiety, and suicidal ideation [4]. The sudden onset, recurrent episodes, and unpredictable course of hair loss can lead to difficulties at work, at school and in relationships [5].

A report from the U.S. Food and Drug Administration’s Patient Focused Drug Development Initiative concluded that: alopecia areata places significant burden on daily life and has a severe impact on how patients feel and function; and symptoms can have considerable detrimental effects on a patient’s quality of emotional well-being, social interactions and ability to lead a normal life [6]. The profound and psychologically devastating impacts of alopecia areata make it necessary and reasonable that patients with the disease seek treatment [7,8].

In June 2022, the U.S. Food and Drug Administration approved baricitinib (Olumiant) for the treatment of alopecia areata, marking the first approved treatment for the disease [9]. Baricitinib and other drugs in the Janus kinase (JAK) inhibitor class have been shown to be effective treatments for alopecia areata [10,11]. These treatments are immunomodulating agents that stimulate hair regrowth and their use must be continued to maintain their effect.

It is entirely reasonable and necessary for the cost of these treatments to be reimbursed. I would be happy to provide any additional information.

Sincerely,

Lisa Anderson, PhD
Research Director
References:


Sample Appeal Letter
For Janus Kinase Inhibitor

[Date]
[Address for Claims Review Department of Insurance Company]

Name of Insured: [insert]
Patient’s Date of Birth: [insert]
Medical Policy #: [insert]

Dear [Name or Claims Review Department]:

I am writing to appeal insurance denial of coverage for Olumiant (baricitinib) for my patient, [name of patient], a [age] year old [man or woman] with [alopecia areata or alopecia totalis or alopecia universalis] who has been under my care since [month and year]. [Describe clinically relevant aspects of patient's alopecia areata].

Alopecia areata is a disfiguring autoimmune disease that causes patches of hair loss on the scalp and can progress to total scalp hair loss (alopecia totalis) or complete loss of eyebrows, eyelashes, facial and other body hair (alopecia universalis). Alopecia areata is psychologically devastating and the medical literature details clinical depression and anxiety associated with it (reference below).

[Name of patient] has failed common and uncommon treatments of alopecia universalis including [e.g. prednisone, methotrexate, intralesional kenalog, photochemotherapy, squaric acid, topical steroids].

There is a sizable medical literature supporting the use of Janus kinase (JAK) inhibitors in severe alopecia areata (select references below). Baricitinib (Olumiant) is a JAK inhibitor that was recently approved by the U.S. Food and Drug Administration for the treatment of alopecia areata, marking the first approved treatment for the disease.

Please approve this medicine for [name of patient] so that [he/she] may experience that which the rest of us take for granted: looking and therefore feeling normal. Please contact me if you need any further information.

Sincerely,

[Physician’s Name]
[Physician’s Office Address and Phone Number]
References:


